Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)

被引：7

作者：

Bearz, Alessandra ^{[1
]}

Fratino, Lucia ^{[1
]}

Spazzapan, Simon ^{[1
]}

Berretta, Massimiliano ^{[1
]}

Giacalone, Annalisa ^{[1
]}

Simonelli, Cecilia ^{[1
]}

Tirelli, Umberto ^{[1
]}

机构：

[1] Natl Canc Inst, Div Med Oncol A, Ctr Riferimento Oncol, I-33081 Aviano, PN, Italy

来源：

LUNG CANCER | 2007年 / 55卷 / 01期

关键词：

EGFR inhibitor; non-small cell lung cancer; elderly;

D O I：

10.1016/j.lungcan.2006.09.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：125 / 127

页数：3

共 10 条

[1]

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC) [J].

Cappuzzo, F ;

Bartolini, S ;

Ceresoli, GL ;

Tamberi, S ;

Spreafico, A ;

Lombardo, L ;

Gregorc, V ;

Toschi, L ;

Calandri, C ;

Villa, E ;

Crinò, L .

BRITISH JOURNAL OF CANCER, 2004, 90 (01) :82-86

[2]

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial [J].

Cella, D ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Heyes, A ;

Ochs, JS ;

Wolf, MK ;

Kay, AC ;

Kris, MG ;

Natale, RB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2946-2954

[3]

RELIABILITY AND VALIDITY OF THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY - LUNG (FACT-L) QUALITY-OF-LIFE INSTRUMENT [J].

CELLA, DF ;

BONOMI, AE ;

LLOYD, SR ;

TULSKY, DS ;

KAPLAN, E ;

BONOMI, P .

LUNG CANCER, 1995, 12 (03) :199-220

[4]

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[5]

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer [J].

Gridelli, C ;

Maione, P ;

Castaldo, V ;

Rossi, A .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1827-1829

[6]

Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study [J].

Janssen-Heijnen, MLG ;

Schipper, RM ;

Razenberg, PPA ;

Crommelin, MA ;

Coebergh, JWW .

LUNG CANCER, 1998, 21 (02) :105-113

[7]

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[8]

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer [J].

Miller, VA ;

Kris, WG ;

Shah, N ;

Patel, J ;

Azzoli, C ;

Gomez, J ;

Krug, LM ;

Pao, W ;

Rizvi, N ;

Pizzo, B ;

Tyson, L ;

Venkatraman, E ;

Ben-Porar, L ;

Memoli, N ;

Zakowski, M ;

Rusch, V ;

Heelan, RT .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1103-1109

[9]

NATALE RB, 2002, P AM SOC CLIN ONCOLO, V21

[10]

Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

← 1 →